Immunotherapy Treating GI Cancer
Shenzhen Geno-Immune Medical Institute
View at source ↗Clinical trial
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Brief summary
The primary objectives are to evaluate the safety and efficacy of infusion of autologous gastro-intestinal (GI) cancer antigen-specific engineered immune effector cells (EIE).
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Trial details
- status
- NOT_YET_RECRUITING
- phase
- PHASE1, PHASE2
- study type
- INTERVENTIONAL
- enrollment
- 100
- sponsor
- Shenzhen Geno-Immune Medical Institute
- conditions
- Cancer
- interventions
- BIOLOGICAL: engineered immune cells
- start date
- 2027-06-01
- start date type
- ESTIMATED
- primary completion date
- 2028-06-30
- has results
- false
- data source
- ClinicalTrials.gov
- data processed
- 2026-10-29T09:00:05
- modifications
- selected fields only; whitespace normalized; brief summary truncated to 2,000 characters
Record
- Archive ID
- nct:NCT03614650
- Published
- Aug 3, 2018
- Updated
- Aug 26, 2026
- Venue
- ClinicalTrials.gov
- ClinicalTrials.gov
- NCT03614650
- Categories
- Cancer
- License
- ClinicalTrials.gov terms (attribution, processing date, modifications noted)
- Provenance
- clinicaltrials